ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder Seasoned biotech entrepreneur Dr Rudi Pauwels joins ANeuroTech as Executive Chairman Alken, Belgium – July 5, 2022: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announces that following a successful pre-IND meeting, the US Food and ...
